✦ LIBER ✦

Toremifene increases BMD despite androgen deprivation therapy

Book ID: 120851667
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2006
Weight: 133 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200615190-00026

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Toremifene a strong option in androgen-d

Toremifene a strong option in androgen-deprivation therapy

✍ Cheeseman, M 📂 Article 📅 2008 🏛 Adis International Limited (now part of Wolters Kl ⚖ 177 KB

Increased fracture risk with androgen-de

Increased fracture risk with androgen-deprivation therapy

📂 Article 📅 2005 🏛 Adis International Limited (now part of Wolters Kl ⚖ 120 KB

Toremifene to Reduce Fracture Risk in Me

Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

✍ Smith, Matthew R.; Morton, Ronald A.; Barnette, K. Gary; Sieber, Paul R.; Malkow 📂 Article 📅 2013 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 547 KB

Toremifene to Reduce Fracture Risk in Me

Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

✍ Smith, Matthew R.; Morton, Ronald A.; Barnette, K. Gary; Sieber, Paul R.; Malkow 📂 Article 📅 2010 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 266 KB

Re: Toremifene to Reduce Fracture Risk i

Re: Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

✍ Langley, Ruth E.; Cafferty, Fay H.; Pollock, Philip A.; Price, Patricia; Abel, P 📂 Article 📅 2011 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 69 KB

Androgen deprivation therapy increases c

Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer

✍ Christopher S. Saigal; John L. Gore; Tracey L. Krupski; Janet Hanley; Matthias S 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB

## Abstract ## BACKGROUND. The use of androgen deprivation therapy (ADT) in the treatment of men with prostate cancer has risen sharply. Although cardiovascular disease is the most common reason for death among men with prostate cancer who do not die of the disease itself, data regarding the effec